AstraZeneca slides after report of Bristol Myers merger talks leaves analysts 'perplexed'

Skip NavigationMarketsPre-MarketsU.S. MarketsCurrenciesPrediction MarketsCryptocurrencyFutures & CommoditiesBondsFunds & ETFsBusinessEconomyFinanceHealth & ScienceMediaReal EstateEnergyClimateTransportationInvestigationsIndustrialsRetailWealthSportsLifeSmall BusinessInvestingPersonal FinanceFintechFinancial AdvisorsOptions ActionETF StreetBuffett ArchiveEarningsTrader TalkTechCybersecurityAIEnterpriseInternetMediaMobileSocial MediaCNBC Disruptor 50Tech GuidePolitics & PolicyWhite HousePolicyDefenseCongressExpanding OpportunityVideoLatest VideoFull EpisodesLivestreamLive AudioLive TV ScheduleCNBC PodcastsCEO InterviewsCNBC DocumentariesDigital OriginalsWatchlistInvesting ClubTrust PortfolioAnalysisTrade AlertsMeeting VideosHomestretchJim's ColumnsEducationSubscribePROPro NewsJosh BrownMike SantoliCalls of the DayMy PortfolioLivestreamFull EpisodesStock ScreenerMarket ForecastOptions InvestingChart InvestingSubscribeLivestreamMenuMake ItselectUSAINTLLivestreamSearch quotes, news & videosLivestreamWatchlistSIGN INCreate free accountMarketsBusinessInvestingTechPolitics & PolicyVideoWatchlistInvesting ClubPROLivestreamMenu (function() { const userMembershipOnLastVisit = localStorage.getItem("cnbcMeta__cachedUserMembership"); if (!userMembershipOnLastVisit) { // If no user membership is stored, user is likely not logged in. // These users will typically see the banner. return; } const { isPro, isInvestingClubUser } = JSON.parse(userMembershipOnLastVisit); if (!(isPro || isInvestingClubUser)) { // We’re rendering the top banner for users who are not pro or investing club members. return; } // Hide the banner for pro and investing club users. const style = document.createElement("style"); style.id = "top-banner-placeholder-style"; style.innerHTML = "[data-top-banner-placeholder] { display: none; }"; document.head.appendChild(style); })() MarketsAstraZeneca slides after report of Bristol Myers merger talks leaves analysts 'perplexed'Published Mon, Aug 3 20263:17 AM EDTUpdated 44 Min AgoElsa OhlenWATCH LIVEKey PointsAstraZeneca is reportedly in talks with U.S. peer Bristol Myers Squibb over a megadeal.If completed, a combined company could be valued at roughly roughly $400 billion.Analysts were perplexed over the news.In this article.FTSEAZN-GBBMYFollow your favorite stocksCREATE FREE ACCOUNTAstraZeneca shares dropped as much as 7% after a report that the U.K.'s largest drugmaker was in talks with U.S. peer Bristol Myers Squibb over a megadeal that, if completed, could value the companies at roughly $400 billion.AstraZeneca declined to comment. Bristol Myers Squibb didn't immediately respond to a request to comment outside of normal working hours. The companies have discussed a potential merger over several months, the Financial Times reported on Sunday. It would be one of the biggest pharmaceutical deals ever. AstraZeneca's London-listed shares were last seen trading 6% lower in early morning trading, weighing on the U.K.'s blue-chip index FTSE 100, which was largely flat.Shares of Bristol Myers rose 3.8% in U.S. premarket trading. Stock Chart IconStock chart iconAstraZeneca and Bristol Myers Squibb shares over the past 12 months. Coming into Monday trading, AstraZeneca had a market cap of $264 billion. That number has risen steadily over the past decade and since CEO Pascal Soriot took the reins in 2012 as the company has developed a solid pipeline of new drugs. It is targeting $80 billion in sales by 2030, up from $58.7 billion last year.Bristol Myers' market cap is roughly $133 billion. While details are scarce and sources told the FT a deal may still not come together, analysts were puzzled by the news. "Given the strength of AZ's growth and innovation profile, we are a bit perplexed," Jefferies analysts